Codexis, which develops industrial biocatalysts for manufacturing applications in the pharmaceutical and biofuels industries, filed on Monday with the SEC to raise up to $100 million in an initial public offering. The company had previously filed for an IPO in April 2008 but withdrew its plans later that year due to market conditions. The Redwood City, CA-based company was founded as a subsidiary of Maxygen in January of 2002 and commenced independent operations in March of the same year. Codexis booked $77 million in sales over the last 12 months and plans to list on the NASDAQ under the symbol CDXS. Credit Suisse and Goldman Sachs are the lead underwriters on the deal. Pricing terms and timing were not disclosed.
